Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
- Conditions
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00464217
- Locations
- 🇪🇸
Hospital Xeral, Lugo, Spain
🇪🇸Hospital General, Castellón, Spain
🇪🇸Hospital Ciudad de Jaén, Jaen, Spain
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2019-02-15
- Target Recruit Count
- 470
- Registration Number
- NCT00458848
- Locations
- 🇮🇹
Ospedale S. Donato, Arezzo, Italy
🇮🇹S.G. Moscati Hospital, Avellino, Italy
🇮🇹Ospedale Binaghi, Cagliari, Italy
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 175
- Registration Number
- NCT00422591
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00413166
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
- Conditions
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 300
- Registration Number
- NCT00408278
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
🇪🇸Hospital de Cruces, Santander, Spain
🇪🇸Hospital de Santiago de Compostela, Santiago de Compostela, Spain
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- University of Kentucky
- Target Recruit Count
- 55
- Registration Number
- NCT00382954
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Previously Treated Myelodysplastic SyndromesAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Blastic Phase Chronic Myelogenous LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00331513
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
- Conditions
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2015-09-25
- Target Recruit Count
- 96
- Registration Number
- NCT00317408
- Locations
- 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪Krankenhaus Muenchen Schwabing, Munich, Germany
Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-11-18
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 200
- Registration Number
- NCT00209833
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-07-30
- Target Recruit Count
- 25
- Registration Number
- NCT00210366
- Locations
- 🇮🇹
Servizio Radiochemioterapia - Ospedale San Raffaele, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.